Ann: Appendix 4C - quarterly, page-5

I'll second that A :

And there are a number of potentials:
Othepedics
Intravenous
MSC (Crohns/GVHD)
Japan (excluding JCR)

According to MSB website , we currently have 2 partnered (Teva ;JCR)

The comment by Jason below re a potential  3rd partnering for  a P2 application is interesting as I always envisaged the 3rd deal to be P3 Orthopedics (spinal fusion).

If anyone has access to Jason's note - it would be interesting to understand what P2 application he is referring to ?

Good luck all.

Jason Zhang, Edison Investment Research (5/27/14) "Mesoblast Ltd. intends to initiate a Phase 3 trial of mesenchymal precursor cells in discogenic low back pain later this year, following the successful Phase 2 trial that reported in February. . .now a leading contender in the field, Mesoblast could have five active programs in Phase 3 (two partnered) and four in Phase 2 studies (one partnered) with nine clinical candidates by the end of this year. We expect CEP-41750 to become the leading stem cell therapy for congestive heart failure."